What is a stock summary page? Click here for an overview.
Business Description
Xenetic Biosciences Inc
NAICS : 325411
SIC : 2834
ISIN : US9840152063
Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.87 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -37.17 | |||||
| Beneish M-Score | -3.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.8 | |||||
| 3-Year EBITDA Growth Rate | 21.1 | |||||
| 3-Year EPS without NRI Growth Rate | 22.4 | |||||
| 3-Year FCF Growth Rate | 26.5 | |||||
| 3-Year Book Growth Rate | -34.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 48.6 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.7 | |||||
| 9-Day RSI | 28.58 | |||||
| 14-Day RSI | 32.01 | |||||
| 3-1 Month Momentum % | -7.49 | |||||
| 6-1 Month Momentum % | -0.23 | |||||
| 12-1 Month Momentum % | -4.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.37 | |||||
| Quick Ratio | 7.37 | |||||
| Cash Ratio | 6.9 | |||||
| Days Sales Outstanding | 104.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.7 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -168.12 | |||||
| Net Margin % | -158.44 | |||||
| FCF Margin % | -112.68 | |||||
| ROE % | -50.83 | |||||
| ROA % | -45.03 | |||||
| ROIC % | -470.34 | |||||
| 3-Year ROIIC % | -190.26 | |||||
| ROC (Joel Greenblatt) % | -1017.68 | |||||
| ROCE % | -53.94 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.02 | |||||
| PB Ratio | 0.84 | |||||
| Price-to-Tangible-Book | 0.84 | |||||
| EV-to-EBIT | 0.27 | |||||
| EV-to-EBITDA | 0.27 | |||||
| EV-to-Revenue | -0.45 | |||||
| EV-to-Forward-Revenue | 0.02 | |||||
| EV-to-FCF | 0.4 | |||||
| Price-to-GF-Value | 0.72 | |||||
| Price-to-Net-Current-Asset-Value | 0.88 | |||||
| Price-to-Net-Cash | 0.95 | |||||
| Earnings Yield (Greenblatt) % | 370.37 | |||||
| FCF Yield % | -56.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xenetic Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.5 | ||
| EPS (TTM) ($) | -2.57 | ||
| Beta | 2.29 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.09 | ||
| Volatility % | 27.64 | ||
| 14-Day RSI | 32.01 | ||
| 14-Day ATR ($) | 0.169411 | ||
| 20-Day SMA ($) | 3.58595 | ||
| 12-1 Month Momentum % | -4.49 | ||
| 52-Week Range ($) | 2.78 - 5.2 | ||
| Shares Outstanding (Mil) | 1.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xenetic Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xenetic Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xenetic Biosciences Inc Frequently Asked Questions
What is Xenetic Biosciences Inc(XBIO)'s stock price today?
The current price of XBIO is $3.26. The 52 week high of XBIO is $5.20 and 52 week low is $2.78.
When is next earnings date of Xenetic Biosciences Inc(XBIO)?
The next earnings date of Xenetic Biosciences Inc(XBIO) is .
Does Xenetic Biosciences Inc(XBIO) pay dividends? If so, how much?
Xenetic Biosciences Inc(XBIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers